rs370194991
Variant summary
Our verdict is Benign. The variant received -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_001105206.3(LAMA4):c.1503T>A(p.Asp501Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000446 in 1,613,488 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_001105206.3 missense
Scores
Clinical Significance
Conservation
Publications
- dilated cardiomyopathy 1JJInheritance: AD Classification: STRONG, MODERATE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), Illumina
- familial isolated dilated cardiomyopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- dilated cardiomyopathyInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -8 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| LAMA4 | NM_001105206.3 | c.1503T>A | p.Asp501Glu | missense_variant | Exon 12 of 39 | ENST00000230538.12 | NP_001098676.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| LAMA4 | ENST00000230538.12 | c.1503T>A | p.Asp501Glu | missense_variant | Exon 12 of 39 | 1 | NM_001105206.3 | ENSP00000230538.7 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152156Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000716 AC: 18AN: 251310 AF XY: 0.0000368 show subpopulations
GnomAD4 exome AF: 0.0000452 AC: 66AN: 1461332Hom.: 0 Cov.: 29 AF XY: 0.0000371 AC XY: 27AN XY: 726970 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152156Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74314 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Dilated cardiomyopathy 1JJ Uncertain:2
This sequence change replaces aspartic acid, which is acidic and polar, with glutamic acid, which is acidic and polar, at codon 494 of the LAMA4 protein (p.Asp494Glu). This variant is present in population databases (rs370194991, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with LAMA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 228778). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt LAMA4 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
not specified Uncertain:1
The p.Asp494Glu variant in LAMA4 has not been previously reported in individuals with cardiomyopathy, but has been identified in 2/11570 Latino chromosomes by t he Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs3 70194991). Computational prediction tools and conservation analysis suggest that the p.Asp494Glu variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical signi ficance of the p.Asp494Glu variant is uncertain.
Cardiovascular phenotype Uncertain:1
The c.1482T>A (p.D494E) alteration is located in exon 12 (coding exon 11) of the LAMA4 gene. This alteration results from a T to A substitution at nucleotide position 1482, causing the aspartic acid (D) at amino acid position 494 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at